BRIDGEWATER, N.J., Oct. 16,
2024 /PRNewswire/ -- Sanofi announced today it will
contribute $18 million to three
Historically Black Medical Schools to help the institutions work to
increase diversity in clinical studies. The investment over 10
years is aimed at strengthening Centers of Excellence in clinical
study diversity at Howard University
College of Medicine, Meharry Medical
College, and Morehouse School of
Medicine.
Funding will be used to hire clinical research staff, establish
infrastructure such as online chat services and pharmacy upgrades,
create customized training programs, and more. Each of the Centers
of Excellence have their own specific needs, which will help them
harness their insights into the underrepresented communities they
serve as they seek to increase representation and improve diversity
in clinical studies.
Lionel Bascles
SVP, Global Head of Clinical Trials and Operations, Sanofi
"At Sanofi, our mission is to chase the miracles of science to
improve people's lives, and this means all people's lives,
regardless of their race or ethnicity. By partnering with these
three esteemed Historically Black College and University medical
schools, we hope to facilitate new inroads to communities that have
been underrepresented in healthcare for far too long. Increasing
diversity and inclusion is essential to the research and
development of medicines and vaccines for people of all
backgrounds."
Valerie Montgomery
Rice, MD, FACOG
President and CEO, Morehouse School of Medicine
"Morehouse School of Medicine is
exceptionally grateful to Sanofi for this investment in our
clinical study diversity Center of Excellence. We look forward to a
robust partnership as we work to increase diversity in clinical
studies and develop advanced opportunities for researchers, leading
to greater health equity. More diversity in clinical studies will
ensure traditionally underserved populations receive the very
latest cutting-edge therapeutic innovations."
Sanofi is a global innovator in the Diversity, Equity and
Inclusion space, including by pioneering the international effort A
Million Conversations to examine trust gaps in the healthcare
system. In the U.S., Sanofi and the National Association for the
Advancement of Colored People (NAACP) announced a strategic
partnership in July that is aimed at advancing health equity for
Black and underserved communities.
About Sanofi
We are an innovative global healthcare
company, driven by one purpose: we chase the miracles of science to
improve people's lives. Our team, across the world, is dedicated to
transforming the practice of medicine by working to turn the
impossible into the possible. We provide potentially life-changing
treatment options and life-saving vaccine protection to millions of
people globally, while putting sustainability and social
responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
Media Relations
Sandrine Guendoul | +
33 6 25 09 14 25 | sandrine.guendoul@sanofi.com
Evan Berland | +1 215 432
0234 | evan.berland@sanofi.com
Timothy Gilbert | + 1 516 521 2929 |
timothy.gilbert@sanofi.com
Investor Relations
Thomas
Kudsk Larsen |+ 44 7545 513 693 |
thomas.larsen@sanofi.com
Alizé Kaisserian | + 33 6 47 04 12
11 | alize.kaisserian@sanofi.com
Arnaud Delépine | + 33 6 73 69 36 93 |
arnaud.delepine@sanofi.com
Corentine Driancourt | + 33 6 40 56 92 21 |
corentine.driancourt@sanofi.com
Felix Lauscher | + 1 908 612 7239 |
felix.lauscher@sanofi.com
Tarik Elgoutni| + 1 617 710 3587
| tarik.elgoutni@sanofi.com
Nathalie Pham | + 33 7 85 93 30 17 |
nathalie.pham@sanofi.com
Sanofi Forward-Looking Statements
This press release
contains forward-looking statements as defined in the Private
Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions, and expectations with respect to future financial
results, events, operations, services, product development and
potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words
"expects", "anticipates", "believes", "intends", "estimates",
"plans" and similar expressions. Although Sanofi's management
believes that the expectations reflected in such forward-looking
statements are reasonable, investors are cautioned that
forward-looking information and statements are subject to various
risks and uncertainties, many of which are difficult to predict and
generally beyond the control of Sanofi, that could cause actual
results and developments to differ materially from those expressed
in, or implied or projected by, the forward-looking information and
statements. These risks and uncertainties include among other
things, the uncertainties inherent in research and development,
future clinical data and analysis, including post marketing,
decisions by regulatory authorities, such as the FDA or the EMA,
regarding whether and when to approve any drug, device or
biological application that may be filed for any such product
candidates as well as their decisions regarding labelling and other
matters that could affect the availability or commercial potential
of such product candidates, the fact that product candidates if
approved may not be commercially successful, the future approval
and commercial success of therapeutic alternatives, Sanofi's
ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks
associated with intellectual property and any related pending or
future litigation and the ultimate outcome of such
litigation, trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment
initiatives and subsequent changes thereto, and the impact that
pandemics or other global crises may have on us, our customers,
suppliers, vendors, and other business partners, and the financial
condition of any one of them, as well as on our employees and on
the global economy as a whole. The risks and uncertainties
also include the uncertainties discussed or identified in the
public filings with the SEC and the AMF made by Sanofi, including
those listed under "Risk Factors" and "Cautionary Statement
Regarding Forward-Looking Statements" in Sanofi's annual report on
Form 20-F for the year ended December 31,
2023. Other than as required by applicable law, Sanofi does
not undertake any obligation to update or revise any
forward-looking information or statements.
All trademarks mentioned in this press release are the property
of the Sanofi group.
View original
content:https://www.prnewswire.com/news-releases/sanofi-commits-18-million-to-howard-university-college-of-medicine-meharry-medical-college-and-morehouse-school-of-medicine-to-increase-diversity-in-clinical-studies-302276979.html
SOURCE Sanofi
